Loading
A phase 1/2 trial of TNG456, Abemaciclib in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., now recruiting.
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is a phase 1/2 interventional study registered as NCT06810544 by Tango Therapeutics, Inc., with 191 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-03-31. Interventions recorded: TNG456, abemaciclib. Conditions listed: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Abemaciclib, CDK4/6 inhibitors, Glioma & glioblastoma.
Shares Abemaciclib, CDK4/6 inhibitors.
Shares Abemaciclib, CDK4/6 inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Abemaciclib, CDK4/6 inhibitors.
Shares Abemaciclib, CDK4/6 inhibitors.
Shares Abemaciclib, CDK4/6 inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/